Cargando…
Evaluation of the pharmacokinetics of trazpiroben (TAK‐906) in the presence and absence of the proton pump inhibitor esomeprazole
Trazpiroben, a dopamine D(2)/D(3) receptor antagonist under development to treat gastroparesis, displays decreasing solubility with increasing pH. This single‐sequence, open‐label, two‐period, crossover study evaluated the effect of esomeprazole, a proton pump inhibitor that raises gastric pH, on th...
Autores principales: | Kaur Mukker, Jatinder, Dukes, George, Wang, Lisi, Huh, Susanna, Khudyakov, Polyna, Nishihara, Mitsuhiro, Chen, Chunlin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9099131/ https://www.ncbi.nlm.nih.gov/pubmed/35218604 http://dx.doi.org/10.1111/cts.13248 |
Ejemplares similares
-
The pharmacokinetics of oral trazpiroben (TAK‐906) after organic anion transporting polypeptide 1B1/1B3 inhibition: A phase I, randomized study
por: Mukker, Jatinder K., et al.
Publicado: (2022) -
Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D(2)/D(3) Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor
por: Chen, Chunlin, et al.
Publicado: (2021) -
Non-Clinical Safety Pharmacology Evaluations of Trazpiroben (TAK-906), a Novel Dopamine D(2)/D(3) Selective Receptor Antagonist for the Management of Gastroparesis
por: Kreckler, Laura, et al.
Publicado: (2022) -
Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK‐906), a Novel Selective D(2)/D(3) Receptor Antagonist: A Phase 1 Randomized, Placebo‐Controlled Single‐ and Multiple‐Dose Escalation Study in Healthy Participants
por: Whiting, Roger L., et al.
Publicado: (2021) -
A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK‐041 in healthy participants and patients with stable schizophrenia
por: Yin, Wei, et al.
Publicado: (2022)